SCHEMBL4700702

SCHEMBL4700702

Cc1ccc(NC(=O)c2ccsc2)cc1-c1ccc(C(=O)NCc2ccc(N3CCN(C)CC3)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 8/20 0.64
KMT2A Q03164 2/20 0.59
LCK P06239 4/20 0.53
CSF1R P07333 4/20 0.53
NPC1 O15118 3/20 0.51
RAB9A P51151 3/20 0.51
KDM1A O60341 1/20 0.50
HDAC1 Q13547 1/20 0.50
KDR P35968 3/20 0.48
EGFR P00533 1/20 0.48
ERBB4 Q15303 1/20 0.48
FLT3 P36888 2/20 0.47
ABL1 P00519 1/20 0.47
AURKA O14965 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5371754 0.86 MAPK14 (0.68) MAPK14KMT2ALCKCSF1RHDAC1
SCHEMBL2352730 0.84 MAPK14 (0.71) MAPK14KMT2ALCKCSF1RNPC1
SCHEMBL4702294 0.83 MAPK14 (0.68) MAPK14KMT2ALCKCSF1RKDR
SCHEMBL4700637 0.83 MAPK14 (0.61) MAPK14KMT2ALCKCSF1RNPC1
SCHEMBL5381526 0.82 MAPK14 (0.68) MAPK14KMT2ALCKCSF1R
SCHEMBL4700686 0.82 MAPK14 (0.66) MAPK14KMT2ALCKCSF1RKDR
SCHEMBL2341989 0.81 MAPK14 (0.55) MAPK14KMT2ANPC1RAB9AMEN1
SCHEMBL5381537 0.80 MAPK14 (0.65) MAPK14KMT2A
SCHEMBL2349181 0.79 MAPK14 (0.63) MAPK14KMT2ANPC1RAB9AKDM1A
SCHEMBL4700921 0.79 LCK (0.63) MAPK14LCKCSF1RRAB9AKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1436272-B1 BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-05-07 EP claimed
US-7309800-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-12-18 US claimed
US-20070105860-A1 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors GLAXO GROUP LIMITED 2007-05-10 US claimed
US-7151118-B2 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors GLAXO GROUP LIMITED (GB) 2006-12-19 US claimed
EP-1436272-B1 BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38 KINASE INHIBITORS GLAXO GROUP LTD (GB) 2008-05-07 EP disclosed
US-7309800-B2 Biphenylcarboxylic amide derivatives as p38 kinase inhibitors GLAXO GROUP LIMITED (GB) 2007-12-18 US disclosed
US-20070105860-A1 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors GLAXO GROUP LIMITED 2007-05-10 US disclosed
US-7151118-B2 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors GLAXO GROUP LIMITED (GB) 2006-12-19 US disclosed
US-20050020540-A1 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors GLAXO GROUP LIMITED (GB) 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105860-A1 Biphenylcarboxylic Amide Derivatives as p38 Kinase Inhibitors MAPK1, MAPKAPK2, MAPK3 MAPK14 6/4885KMT2A 2970/4885LCK 61/4885
US-20050020540-A1 Biphenylcarboxylic amide derivatives as p38-kinase inhibitors MAPK1, MAPKAPK2, MAP3K1 MAPK14 32/4885KMT2A 2732/4885LCK 91/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.